Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.
CAR-T cell therapy presents numerous challenges for cell therapy developers who are looking to move towards commercialization. The move from development to commercial ...
Cell-based therapies are rapidly changing the way the medical industry is treating a wide range of diseases. As the development of these therapies continues to advance, ...
Cell therapies are at the forefront of saving lives – providing critical treatments to patients who might otherwise have very few viable options. Because these therapies ...
On Thursday, February 23 from 2:00 – 3:30 PM EST, Sanjin Zvonic, PhD, PCT’s Senior Director, Business Leader, Clinical Cell Therapy Manufacturing, will be speaking as ...
While using cell therapies that have a short shelf-life due to a “fresh” final product (meaning the product is not designed for long-term storage) is perfectly ...
This is the third in a three-part series (read Part 1 and Part 2 for the complete picture). As you approach cell therapy commercialization—having traveled what is still ...
The following is a guest blog by Kevin O’Donnell, Vice President, Cold Chain Standards, Practices & Compliance, BioLife Solutions As forecast by the White House 2012 ...
This is the second in a three-part series (Part 1 can be found here). As you enter this mid-phase of development, we reflect on these words from Albert Einstein: “In the ...
If you’re reading this, you’ve no doubt already discovered that cell therapy manufacturing comes with its share of specific challenges, no matter what phase of ...